DURECT appoints Board member Gail Maderis as Chair of the Board of Directors

– USA, CA –  DURECT Corporation (Nasdaq: DRRX) today announced the appointment of Gail Maderis as Chair of the Board of Directors, effective March 17, 2023, succeeding David Hoffmann who will retire from the board on June 21, 2023.

Gail Maderis has been on the DURECT Board since January 2021, serving on the Audit and Compensation committees.

About Gail Maderis

Ms. Maderis has served as President and CEO of Antiva Biosciences, a venture-funded biopharma company developing topical therapies to treat the pre-cancerous lesions caused by HPV, since 2015. From 2009 to 2015, she led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, she served as President and CEO of Five Prime Therapeutics, Inc., a protein discovery and development company. Before FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology. She also practiced management and strategy consulting with Bain & Co. She serves on the corporate board of Valitor, Inc., as well as on the non-profit boards of BIO (Emerging Company and Health Sections), CLSI, The Termeer Foundation and the University of California Berkeley Foundation Board of Trustees.

Ms. Maderis said, “I am honored to be elected to serve as Chair of DURECT’s Board of Directors. This is a transformational period for DURECT and I look forward to continuing to work with Jim and his leadership team to bring larsucosterol to patients as potentially the first approved therapy for alcohol-associated hepatitis.”

She received a BS in business from UC Berkeley and an MBA from Harvard Business School.


DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis is also being explored. In addition, POSIMIR for infiltration use, a non-opioid analgesic utilizing the innovative SABER platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for commercialization in the United States.

For more information: https://www.durect.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.